Cardio Diagnostics Holdings, Inc. and Southdale YMCA Announce New Heart Health Partnership to Serve the Edina, Minnesota Community

Key Terms

epigenetics medical

Epigenetics is the study of how environmental factors and experiences can influence how genes are turned on or off without changing the underlying genetic code. Think of it like a dimmer switch for a light, adjusting the brightness without altering the bulb itself. This process can affect health, behavior, and even how diseases develop, which is important for investors interested in long-term trends in medicine, wellness, and biotech industries.

telemedicine technical

Telemedicine is the delivery of healthcare services remotely through digital communication tools, such as video calls or online messaging. It allows patients to consult with doctors and medical professionals without visiting a clinic in person. For investors, telemedicine represents a growing sector that combines technology and healthcare, potentially transforming how medical care is accessed and delivered worldwide.

coronary heart disease medical

Coronary heart disease is a condition in which the blood vessels that supply the heart become narrowed or blocked, reducing oxygen flow and raising the risk of chest pain, heart attacks, and heart failure; think of it like plumbing pipes in which buildup restricts flow. It matters to investors because prevalence, treatments, and outcomes drive demand for drugs, medical devices, hospital services, and insurance costs, and clinical or regulatory developments related to the disease can quickly move stock prices.

cardiovascular medical

Relating to the heart and the network of blood vessels that pump and carry blood through the body — like the body’s engine and plumbing working together. Investors pay attention because conditions, treatments, devices, and drugs tied to this system drive large health care spending, regulatory reviews, and market demand; breakthroughs, safety issues, or trial results can quickly change a company’s revenue prospects and stock value.

Southdale YMCA, part of YMCA of the North, becomes the second YMCA location nationally to partner with Cardio Diagnostics, expanding community access to AI-powered cardiovascular testing and education

EDINA, Minn. & CHICAGO--(BUSINESS WIRE)-- Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO), an AI-powered precision cardiovascular medicine company, today announced a new partnership with the Southdale YMCA to bring expanded heart health education and advanced cardiovascular testing to their members and the broader Edina community. The Southdale YMCA primarily serves the Edina, Richfield, Bloomington, and South Minneapolis areas, supporting more than 14,000 individuals, approximately 80% of whom are adults.

This collaboration builds on Cardio Diagnostics’ growing engagement with YMCAs nationwide, following its inaugural partnership with the YMCA of East Tennessee.

Heart disease remains a persistent challenge nationally. In Minnesota, approximately 17% of all deaths are due to heart disease. These numbers highlight the importance of bringing meaningful heart health resources directly to Minnesota communities like Edina. By combining community-based education with innovative testing options, Cardio Diagnostics and the Southdale YMCA aim to help YMCA members and Edina residents better understand and manage their cardiovascular risk.

New 2026 Community Offerings

As part of the collaboration, Cardio Diagnostics will host an in-person heart health education event on January 26^th at 11.30am CT at the Southdale YMCA. The session will be led by Dr. Robert Philibert, MD, Ph.D., Chief Medical Officer of Cardio Diagnostics, and will offer community members practical guidance on reducing their risk of heart disease, understanding their individual cardiovascular profile, and using modern tools to support long-term heart health. Additional members of the Cardio Diagnostics team will also be on site to engage with attendees and answer questions.

This educational event will lead into the Southdale YMCA Heart Health Fair on February 25^th between 8am-4pm CT, offering members the opportunity to explore heart health resources, ask questions, and access Cardio Diagnostics’ physician-ordered tests with onsite blood sample collection available.

Access to Advanced Testing for the Community

Throughout the program, Southdale YMCA members and the Edina community will have access to discounted prices for Epi+Gen CHD™ and PrecisionCHD™, two clinically validated tests developed by Cardio Diagnostics.

Epi+Gen CHD™ provides a three-year risk assessment for a coronary heart disease (CHD) event, including heart attack risk.

PrecisionCHD™ assists in the diagnosis and management of CHD.

Both tests use a simple blood draw and are powered by epigenetics and AI. The tests will be available through Cardio Diagnostics’ telemedicine partner, with the option to receive an at-home kit or complete sample collection at the Heart Health Fair.

“We are excited to partner with the Southdale YMCA to bring our precision cardiovascular tools to the local community,” said Meesha Dogan, Ph.D., CEO and Co-Founder of Cardio Diagnostics. “Heart disease is often preventable when detected early, and this collaboration gives more individuals an opportunity to be proactive about their heart health.”

“The Southdale YMCA is committed to helping individuals thrive throughout every stage of life,” said Catherine Quinlivan, Senior Operations Director at Southdale YMCA. “By offering this program that encompasses innovative cardiovascular testing alongside education, this partnership allows us to better support the health and well-being of our members and the broader community.”

About Southdale YMCA

The Southdale YMCA, as a proud member of the nationwide YMCA ecosystem, helps advance the Y’s mission as one of the nation’s leading nonprofits dedicated to youth development, healthy living, and social responsibility. Across the U.S., 2,700 Ys engage 22 million men, women and children - regardless of age, income or background - to nurture the potential of children and teens, improve the nation's health and well-being, and provide opportunities to give back and support neighbors. Anchored in more than 10,000 communities, the Y has the long-standing relationships and physical presence not just to promise, but to deliver, lasting personal and social change. https://www.ymcanorth.org/locations/southdale_ymca

About Cardio Diagnostics

Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention, detection, and management more accessible, personalized, and precise. The Company was formed to further develop and commercialize clinical tests by leveraging a proprietary Artificial Intelligence (AI)-driven Integrated Genetic-Epigenetic Engine ("Core Technology") for cardiovascular disease. For more information, please visit https://cdio.ai/.

Forward-Looking Statements

Certain statements and information included in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Act of 1995. When used in this press release, the words or phrases "will," "will likely result," "expected to," "will continue," "anticipated," "estimate," "projected," "intend," "goal," or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks, known and unknown, and uncertainties, many of which are beyond the control of the Company. Such uncertainties and risks include but are not limited to, our ability to successfully execute our growth strategy, changes in laws or regulations, economic conditions, and dependence on results as discussed in the Annual Report on Form 10-K for the period ended December 31, 2024, under the heading "Risk Factors" in Part I, Item IA thereof, and other documents filed from time to time with the Securities and Exchange Commission. Such factors could materially adversely affect the Company's financial performance and could cause the Company's actual results for future periods to differ materially from any opinions or statements expressed within this press release.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260106960490/en/

Investors

Investor Relations

855-226-9991

investors@cdio.ai

Media & Public Relations

Public Relations

855-226-9991

pr@cdio.ai

Source: Cardio Diagnostics Holdings, Inc.